Format

Send to

Choose Destination
See comment in PubMed Commons below
Blood. 2013 Nov 21;122(22):3547-8. doi: 10.1182/blood-2013-10-528992.

Emergence of crenolanib for FLT3-mutant AML.

Author information

1
HARVARD MEDICAL SCHOOL.

Abstract

In this issue of Blood, Zimmerman and colleagues demonstrate that the tyrosine kinase inhibitor (TKI) crenolanib effectively suppresses growth of leukemic cells harboring both FLT3-ITD and FLT3-TKD mutations, the latter of which are increasingly seen to emerge as resistant mutations after FMS-like tyrosine kinase 3 (FLT3) inhibitor therapy.

PMID:
24263951
DOI:
10.1182/blood-2013-10-528992
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center